This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Other leukaemias of specified cell type
CD2_OTHER_LEUKAEMIA_SPECIFIED
leukemia: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
89 |
4. Check minimum number of eventsNone |
89 |
5. Include endpointsNone |
89 |
6. Filter based on genotype QC (FinnGen only) |
89 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF8
- Parent code in ICD-10
- C81-C96
- Name in latin
- Aliae leuc(h)aemiae typo cellulari specificato
Similar endpoints
↥List of similar endpoints to
Other leukaemias of specified cell type
based on the number of shared cases.
Similar with more cases:
- Other leukaemias of specified cell type
- Primary_lymphoid and hematopoietic malignant neoplasms
- Primary_lymphoid and hematopoietic malignant neoplasms
- Malignant neoplasm
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 89 | 48 | 41 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 54.77 | 52.22 | 57.76 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 80
- Matched controls
- 800
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
127
Kela drug reimbursment
Transplant complication
130.3
31.5
32
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
57.8
31.2
36
11
C94.0
ICD-10 Finland
Acute erythroid leukaemia
+∞
25.3
23
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
23.1
19.9
29
19
L04AA06
ATC
mycophenolic acid; systemic
93.2
19.8
21
*
C94.7
ICD-10 Finland
Other specified leukaemias
+∞
19.6
18
*
XW000
NOMESCO Finland
Bone marrow biopsy
23.2
18.7
27
17
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
17.3
17.3
28
24
L04AD01
ATC
ciclosporin; systemic
30.9
16.1
21
9
L04AA01
ATC
[U] ciclosporin; systemic
34.9
15.1
19
7
ZX120
NOMESCO Finland
Intravenous
12.4
14.9
28
33
WW500
NOMESCO Finland
Blood transfusion
27.1
14.1
19
9
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
+∞
13.9
13
*
Z94.0
ICD-10 Finland
Kidney transplant status
55.7
12.3
14
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
76.4
12.0
13
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
21.8
11.3
16
9
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
125.7
10.7
11
*
TK800
NOMESCO Finland
Hemodialysis
27.8
10.7
14
6
ZX108
NOMESCO Finland
Inhalation
+∞
10.6
10
*
L03AA02
ATC
filgrastim; parenteral
23.8
10.2
14
7
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.8
10.1
54
240
L04AD02
ATC
tacrolimus; systemic (calcineurin inhibitors)
112.7
9.6
10
*
A05AA02
ATC
ursodeoxycholic acid; oral
112.7
9.6
10
*
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
112.7
9.6
10
*
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
7.6
9.5
23
40
H02AB09
ATC
hydrocortisone; systemic
18.5
9.4
14
9
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
21.8
9.3
13
7
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.9
9.0
27
63
R4110
NOMESCO Finland
Physiotherapy
4.6
8.9
38
131
Z49.1
ICD-10 Finland
Extracorporeal dialysis
31.4
8.7
11
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.5
8.7
28
71
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
100.0
8.6
9
*
L01BB02
ATC
mercaptopurine; oral
100.0
8.6
9
*
C94.2
ICD-10 Finland
Acute megakaryoblastic leukaemia
+∞
8.5
8
*
C94.4
ICD-10 Finland
Acute panmyelosis with myelofibrosis
+∞
8.5
8
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
7.1
8.4
21
38
R50.9
ICD-10 Finland
Fever, unspecified
5.3
8.2
27
70
H02AB04
ATC
methylprednisolone; systemic
5.3
8.2
27
70
C03CA01
ATC
furosemide; systemic
4.3
8.2
37
133
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
50.0
7.9
9
*
TGC00
NOMESCO Finland
Bronchial lavation
15.4
7.7
12
9
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
15.4
7.7
12
9
9835/3-C42.1
ICD-O-3
Precursor cell lymphoblastic leukemia, NOS, of bone marrow
87.8
7.5
8
*
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
+∞
7.4
7
*
C94.1
ICD-10 Finland
Chronic erythremia
+∞
7.4
7
*
6BA02
NOMESCO Finland
NA
+∞
7.4
7
*
TAB00
NOMESCO Finland
Lumbar puncture
9.7
7.2
14
17
L04AX01
ATC
azathioprine; systemic
10.8
7.1
13
14
N18.0
ICD-10 Finland
End-stage renal disease
43.9
6.9
8
*
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
43.9
6.9
8
*
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
10.1
6.9
13
15
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
10.1
6.9
13
15
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
9.4
6.6
13
16
A11CC03
ATC
alfacalcidol; systemic
16.0
6.6
10
7
Z94.1
ICD-10 Finland
Heart transplant status
75.5
6.5
7
*
J01MA12
ATC
levofloxacin; systemic
4.1
6.5
28
93
KA1AE
NOMESCO Finland
Kidney ultrasound examination
20.0
6.4
9
5
ZX112
NOMESCO Finland
Subcutaneous
29.2
6.4
8
*
N25.8
ICD-10 Finland
Other disorders resulting from impaired renal tubular function
+∞
6.3
6
*
9961/3-C42.1
ICD-O-3
Primary myelofibrosis of bone marrow
+∞
6.3
6
*
C94.5
ICD-10 Finland
Acute myelofibrosis
+∞
6.3
6
*
J02AC03
ATC
voriconazole; systemic
+∞
6.3
6
*
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
+∞
6.3
6
*
20700
ICD-8 Finland
Other and unspecified leukaemia, Leukaemia, acute
+∞
6.3
6
*
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
6.3
6
*
N18.8
ICD-10 Finland
Other chronic renal failure
14.0
6.3
10
8
J05AB01
ATC
aciclovir; systemic
3.8
6.2
29
103
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
8.4
6.2
13
18
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
7.5
6.2
14
22
A12AA04
ATC
calcium carbonate; oral
16.6
6.1
9
6
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
19
15
15.83
20.08
1.5
1.3
—
—
—
0
0
42
98
7.22
19.19
22.0
7.0
1.1
1.1
mmol/l
0.01
42
92
25
43
7.69
14.94
3.5
1.9
—
—
—
0
0
34
82
6.09
14.54
2.2
1.5
—
—
—
0
0
40
117
5.39
13.67
3.9
1.7
—
—
—
0
0
33
83
5.73
13.37
2.3
1.5
—
—
—
0
0
40
126
4.95
12.32
11.3
3.9
0.8
0.8
mmol/l
0.62
40
115
17
27
7.55
10.70
4.3
2.5
88.7
84.7
%
0.20
17
27
68
349
5.02
10.54
25.9
7.3
1.2
1.2
mmol/l
0.31
62
298
15
21
8.39
10.48
5.5
1.5
—
—
—
0
0
16
25
7.58
10.19
6.1
1.7
—
—
—
0
0
16
25
7.58
10.19
5.4
1.7
—
—
—
0
0
16
25
7.58
10.19
2.3
1.2
—
—
—
0
0
30
96
4.21
8.68
5.5
2.3
2.1
2.4
g/l
1.31
30
90
11
15
8.23
7.73
2.8
1.8
—
—
—
0
0
29
101
3.78
7.33
5.8
2.4
12.1
15.3
umol/l
1.33
29
94
10
5
22.22
7.31
3.8
1.2
—
—
—
0
0
13
23
6.45
7.30
2.4
2.4
—
—
—
0
0
10
13
8.54
7.27
2.3
1.5
—
—
—
0
0
13
24
6.17
7.00
5.3
2.7
218.4
197.0
%
0.37
13
24
13
25
5.92
6.72
3.2
2.3
—
—
—
0
0
17
42
4.77
6.71
2.3
1.5
—
—
—
0
0
49
263
2.92
5.81
7.9
3.3
—
—
—
0
0
10
17
6.50
5.76
2.8
1.4
—
—
—
0
0
42
216
2.79
5.28
5.9
3.1
0.2
0.4
e6/l
0.99
37
154
5
0
+∞
5.25
1.6
0.0
—
—
—
0
0
9
9
10.95
5.15
6.7
1.9
—
—
—
0
0
9
9
10.95
5.15
6.7
1.9
—
—
—
0
0
9
9
10.95
5.15
6.7
1.9
—
—
—
0
0
31
137
2.94
5.15
4.5
2.5
0.9
0.9
e6/l
0.07
21
79
37
183
2.75
4.96
6.6
2.5
—
—
—
0
0
9
12
8.20
4.47
6.0
1.5
—
—
—
0
0
8
9
9.62
4.37
1.9
1.9
2.7
3.8
mg/l
—
8
9
7
6
12.50
4.35
3.1
1.2
—
—
—
0
0
7
6
12.50
4.35
3.6
2.7
—
—
—
0
0
59
384
2.59
4.33
25.3
7.0
11.5
11.4
umol/l
0.03
59
365
17
58
3.39
4.28
8.4
3.9
1.3
1.5
mmol/l
0.11
12
41
28
128
2.73
4.28
5.6
2.6
1.5
2.1
e6/l
0.22
17
70
9
13
7.56
4.28
2.9
1.4
—
—
—
0
0
9
14
7.01
4.09
6.1
1.4
—
—
—
0
0
12
34
3.92
3.92
2.4
1.5
—
—
—
0
0
54
349
2.39
3.86
14.0
4.3
—
—
—
0
0
7
8
9.37
3.84
2.0
1.3
—
—
—
0
0
41
236
2.37
3.81
6.0
3.2
2.3
2.4
mmol/l
0.97
41
203
16
60
3.03
3.45
6.2
4.0
51.4
68.2
ml/min/173m2
—
5
30
43
263
2.23
3.37
1.7
2.0
86.2
92.1
pmol/l
0.35
26
128
12
38
3.49
3.35
10.3
7.6
0.7
0.7
%
0.18
12
38
8
15
5.74
3.27
2.9
1.7
—
—
—
0
0
12
39
3.40
3.23
10.3
7.4
1.4
1.6
%
0.16
12
39
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
10
29
3.76
3.15
4.4
3.0
0.3
0.4
u/ml
—
5
20
45
287
2.15
3.11
6.9
2.5
327.9
105.7
ug/l
3.56
45
264
17
71
2.72
3.02
5.3
4.1
—
—
—
0
0
5
5
10.48
3.01
1.2
1.0
—
—
—
0
0
5
5
10.48
3.01
1.2
1.0
—
—
—
0
0
7
13
5.74
2.93
2.7
1.7
—
—
—
0
0
34
204
2.08
2.68
6.1
4.0
28.4
10.2
mg/mmol
0.78
27
125
8
20
4.29
2.63
1.0
1.2
—
—
—
0
0
8
20
4.29
2.63
1.3
1.3
—
—
—
0
0
8
20
4.29
2.63
1.3
1.3
—
—
—
0
0
51
360
1.98
2.51
6.8
3.3
0.0
0.0
estimate
—
9
65
72
578
2.29
2.46
26.9
7.5
92.3
84.4
u/l
0.50
72
539
5
8
6.54
2.40
1.4
1.0
—
—
—
0
0
7
18
4.13
2.30
8.4
1.2
64.3
374.5
e6/l
—
7
13
7
18
4.13
2.30
8.4
1.1
55.0
2.3
e6/l
—
7
13
50
358
1.91
2.29
8.6
4.5
0.0
0.0
estimate
—
8
69
6
14
4.51
2.19
1.7
1.2
—
—
—
0
0
5
10
5.22
2.10
4.2
1.9
—
—
—
0
0
5
10
5.22
2.10
1.2
1.2
—
—
—
0
0
5
10
5.22
2.10
4.2
1.9
—
—
—
0
0
5
10
5.22
2.10
4.2
1.9
—
—
—
0
0
5
10
5.22
2.10
4.2
1.9
—
—
—
0
0
6
15
4.21
2.07
4.3
1.7
—
—
—
0
0
30
187
1.91
2.05
8.6
3.7
0.0
0.0
estimate
—
7
67
5
11
4.74
1.97
4.2
1.8
—
—
—
0
0
5
11
4.74
1.97
4.2
1.8
—
—
—
0
0
6
17
3.70
1.87
1.7
1.5
—
—
—
0
0
48
357
1.75
1.80
7.1
3.2
0.0
0.0
estimate
—
9
71
7
28
2.62
1.48
3.9
3.4
17.9
325.2
u/ml
—
7
22
37
269
1.64
1.43
7.6
3.5
—
—
—
0
0
10
48
2.22
1.33
21.9
5.3
1.2
1.2
mmol/l
—
10
42
5
20
2.59
1.16
3.2
1.4
59.4
37.8
nmol/l
—
5
20
7
30
2.44
1.15
10.4
2.1
—
—
—
0
0
9
49
1.93
1.02
1.8
2.8
296.9
276.3
ng/l
—
9
44
10
55
1.92
0.96
11.2
4.9
24.6
25.3
mmol/l
—
10
55
6
28
2.22
0.93
4.3
2.0
—
—
—
0
0
6
28
2.22
0.93
2.3
1.2
—
—
—
0
0
6
28
2.22
0.93
2.3
1.2
—
—
—
0
0
6
33
1.88
0.80
10.7
2.5
0.1
0.0
e6/l
—
6
33
0
24
0.00
0.80
0.0
1.2
—
2.2
—
0
13
0
24
0.00
0.80
0.0
1.5
—
3.0
—
0
14
5
26
1.98
0.72
1.2
2.4
—
—
—
0
0
53
474
1.29
0.51
3.0
3.2
—
—
—
0
0
6
43
1.42
0.36
2.3
1.3
—
—
—
0
0
65
687
0.80
0.35
5.9
4.4
5.9
5.9
mmol/l
0.12
59
632
31
275
1.20
0.28
7.7
3.6
37.2
41.9
ng/l
0.11
26
188
77
743
1.27
0.26
58.5
13.6
27.2
22.8
mg/l
0.84
72
561
7
91
0.75
0.24
1.7
2.0
—
—
—
0
0
5
39
1.30
0.23
1.8
1.8
—
—
—
0
0
17
145
1.21
0.22
1.5
1.6
—
—
—
0
0
11
89
1.27
0.22
16.8
6.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
5.4
—
114.5
—
0
10
0
10
0.00
0.21
0.0
1.5
—
21.0
—
0
10
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
51
486
1.12
0.15
6.8
3.2
53.9
49.2
u/l
0.22
51
455
76
777
0.85
0.14
34.4
10.4
27.3
26.2
u/l
0.24
76
756
76
776
0.86
0.12
56.8
15.6
111.4
75.4
umol/l
1.84
76
776
10
113
0.87
0.09
1.1
1.2
5.2
7.9
u/ml
—
5
42
7
83
0.83
0.07
1.6
1.8
—
—
—
0
0
17
182
0.92
0.06
2.6
4.0
34.5
22.5
%
—
8
93
10
106
0.94
0.01
1.8
1.3
—
—
—
0
0
11
116
0.94
0.01
1.0
1.3
17.5
38.3
iu/ml
—
5
44
68
674
1.04
0.00
4.9
4.6
2.0
1.9
mu/l
0.45
63
618
65
652
0.99
0.00
42.9
12.8
70.4
81.7
ml/min/173m2
2.18
58
508
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
5.4
—
0
5
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
13.3
—
0
8
0
6
0.00
0.00
0.0
2.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
3.5
—
43.3
—
0
6
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_OTHER_LEUKAEMIA_SPECIFIED – Other leukaemias of specified cell type
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).